{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:06:37Z","timestamp":1787065597652,"version":"build-2736575974"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T00:00:00Z","timestamp":1635120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>\n                    The treatment of sickle cell disease (SCD) is mainly supportive, except for a minority, who receive bone marrow transplantation (BMT). Serum ferritin (SF) is routinely available but is notoriously unreliable as a tool for iron-overload assessment since it is an acute-phase reactant. Although blood transfusion is one of the most effective ways to deal with specific acute and chronic complications of SCD, this strategy is often associated with alloimmunization, iron overload, and hemolytic reactions. This study, thus, aims to evaluate iron overload in patients with SCD on chronic blood transfusions and specifically, correlate SF with the current standard of care of iron-overload assessment using MRI-based imaging techniques. Amongst a historic cohort of 58 chronically transfused patients with SCD, we were able to evaluate 44 patients who are currently alive and had multiple follow-up testing. Their mean age (\u00b1SD) was 35 (9) years and comprised of 68.2% of women. The studied iron-overload parameters included cardiac T2\n                    <jats:sup>*<\/jats:sup>\n                    MRI, liver iron concentration (LIC) by Liver T2\n                    <jats:sup>*<\/jats:sup>\n                    MRI, and serial SF levels. Additionally, in a smaller cohort, we also studied LIC by FerriScan\n                    <jats:sup>\u00a9<\/jats:sup>\n                    R2-MRI. Chronic blood transfusions were necessary for severe vaso-occlusive crisis (VOC) (38.6%), severe symptomatic anemia (38.6%), past history of stroke (15.9%), and recurrent acute chest syndrome (6.9%). About 14 (24%) patients among the original cohort died following SCD-related complications. Among the patients currently receiving chelation, 26 (96%) are on Deferasirox (DFX) [Jadenu\u00ae (24) or Exjade\u00ae (2)], with good compliance and tolerance. However, one patient is still receiving IV deferoxamine (DFO), in view of the significantly high systemic iron burden. In this evaluable cohort of 44 patients, the mean SF (\u00b1SD) reduced marginally from 4,311 to 4,230 ng\/ml, mean Liver T2\n                    <jats:sup>*<\/jats:sup>\n                    MRI dropped from 12 to 10.3 mg\/gm dry weight, while the mean cardiac T2\n                    <jats:sup>*<\/jats:sup>\n                    MRI improved from 36.8 to 39.5 ms. There was a mild to moderate correlation between the baseline and final values of SF ng\/ml,\n                    <jats:italic>r<\/jats:italic>\n                    = 0.33,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.01; Cardiac T2\n                    <jats:sup>*<\/jats:sup>\n                    MRI ms,\n                    <jats:italic>r<\/jats:italic>\n                    = 0.3,\n                    <jats:italic>p<\/jats:italic>\n                    = 0.02 and Liver T2\n                    <jats:sup>*<\/jats:sup>\n                    MRI mg\/kg dry weight,\n                    <jats:italic>r<\/jats:italic>\n                    = 0.6,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001. Overall, there was a positive correlation between SF and Liver T2\n                    <jats:sup>*<\/jats:sup>\n                    MRI (Pearson's\n                    <jats:italic>r<\/jats:italic>\n                    = 0.78,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001). Cardiac T2\n                    <jats:sup>*<\/jats:sup>\n                    MRI increased with the decreasing SF concentration, showing a negative correlation which was statistically significant (Pearson's\n                    <jats:italic>r<\/jats:italic>\n                    = \u22120.6,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.001). Furthermore, there was an excellent correlation between SF ng\/ml and LIC by FerriScan\n                    <jats:sup>\u00a9<\/jats:sup>\n                    R2-MRI mg\/g or mmol\/kg (Spearmen's rho = \u22120.723,\n                    <jats:italic>p<\/jats:italic>\n                    &amp;lt; 0.008) in a small subset of patients (\n                    <jats:italic>n<\/jats:italic>\n                    = 14) who underwent the procedure. In conclusion, our study demonstrated a good correlation between serial SF and LIC by either Liver MRI T2\n                    <jats:sup>*<\/jats:sup>\n                    or by FerriScan\n                    <jats:sup>\u00a9<\/jats:sup>\n                    R2-MRI, even though SF is an acute-phase reactant. It also confirms the cardiac sparing effect in patients with SCD, even with the significant transfusion-related iron burden. About 14 (24%) patients of the original cohort died over the past 15 years, indicative of a negative impact of iron overload on disease morbidity and mortality.\n                  <\/jats:p>","DOI":"10.3389\/fmed.2021.731102","type":"journal-article","created":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T02:12:15Z","timestamp":1635127935000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Iron Overload in Patients With Heavily Transfused Sickle Cell Disease\u2014Correlation of Serum Ferritin With Cardiac T2* MRI (CMRTools), Liver T2* MRI, and R2-MRI (Ferriscan\u00ae)"],"prefix":"10.3389","volume":"8","author":[{"given":"Salam","family":"Alkindi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinodh","family":"Panjwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Al-Rahbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid","family":"Al-Saidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil V.","family":"Pathare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/S0140-6736(12)61229-X","article-title":"Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates","volume":"381","author":"Piel","year":"2013","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.26719\/2001.7.6.1004","article-title":"A community-based study of common hereditary blood disorders in Oman","volume":"7","author":"Al Riyami","year":"2001","journal-title":"East Mediterr Health J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3109\/03630261003677213","article-title":"Forecasting hemoglobinopathy burden through neonatal screening in Omani neonates","volume":"34","author":"Alkindi","year":"2010","journal-title":"Hemoglobin."},{"key":"B4","first-page":"127","article-title":"Avascular necrosis of the hip in sickle cell disease in Oman: is it serious enough to warrant bone marrow transplantation?","volume":"11","author":"Wali","year":"2011","journal-title":"Sultan Qaboos Univ Med J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.12816\/0003104","article-title":"Deaths from sickle cell disease in intensive care units: can we do better?","volume":"12","author":"Al-Lamki","year":"2012","journal-title":"Sultan Qaboos Univ Med J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"177","DOI":"10.12816\/0003110","article-title":"Adult sickle cell disease: a five-year experience of intensive care management in a University hospital in Oman","volume":"12","author":"Tawfic","year":"2012","journal-title":"Sultan Qaboos Univ Med J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2017028","DOI":"10.4084\/mjhid.2017.028","article-title":"Increased vasoocclusive crises in \u201cO\u201d blood group sickle cell disease patients: association with underlying thrombospondin levels","volume":"9","author":"Al Huneini","year":"2017","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e2017013","DOI":"10.4084\/mjhid.2017.013","article-title":"Alloimmunization in patients with sickle cell disease and thalassemia: experience of a single centre in Oman","volume":"9","author":"Alkindi","year":"2017","journal-title":"Mediterr J Hematol Infect Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e2019058","DOI":"10.4084\/mjhid.2019.058","article-title":"Prevalence of Hepatitis B, Hepatitis C, and HIV in multiply transfused sickle cell disease patients from Oman","volume":"11","author":"Alkindi","year":"2019","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.1038\/s41598-020-59258-y","article-title":"Predictors of impending acute chest syndrome in patients with sickle cell anemia","volume":"10","author":"Alkindi","year":"2020","journal-title":"Sci Rep"},{"key":"B11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/1535370219892846","article-title":"Clinical and laboratory parameters, risk factors predisposing to the development of priapism in sickle cell patients","volume":"245","author":"Alkindi","year":"2020","journal-title":"Exp Biol Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.5001\/omj.2020.89","article-title":"Respiratory viral infections in sickle cell anemia: special emphasis on H1N1 co-infection","volume":"35","author":"Alkindi","year":"2020","journal-title":"Oman Med J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1097\/00062752-200203000-00003","article-title":"Sickle cell vaso-occlusion: multistep and multicellular paradigm","volume":"9","author":"Frenette","year":"2002","journal-title":"Curr Opin Hematol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/10245330310001604719","article-title":"Cytokines in sickle cell disease","volume":"8","author":"Pathare","year":"2003","journal-title":"Hematology."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0609.1998.tb00989.x","article-title":"The management of crisis in sickle cell disease","volume":"60","author":"Okpala","year":"1998","journal-title":"Eur J Haematol."},{"key":"B16","volume-title":"Sickle Cell Disease","author":"Serjeant","year":"2001"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/bmj.294.6581.1206","article-title":"Acute admissions of patients with sickle cell disease who live in Britain","volume":"294","author":"Brozovic","year":"1987","journal-title":"Br Med J."},{"key":"B18","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.1365-2141.2005.05476.x","article-title":"Bone involvement in sickle cell disease","volume":"129","author":"Almeida","year":"2005","journal-title":"Br J Haematol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.18295\/squmj.2018.18.01.002","article-title":"Transfusion in haemoglobinopathies: review and recommendations for local blood banks and transfusion services in Oman","volume":"18","author":"Al-Riyami","year":"2018","journal-title":"Sultan Qaboos Univ Med J"},{"key":"B20","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1182\/bloodadvances.2019001143","article-title":"American Society of Hematology 220 guidelines for sickle cell disease: transfusion support","volume":"4","author":"Chou","year":"2020","journal-title":"Blood Adv."},{"key":"B21","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0022-3476(95)70204-0","article-title":"Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions","volume":"126","author":"Pegelow","year":"1995","journal-title":"J Pediatr."},{"key":"B22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1056\/NEJM199807023390102","article-title":"Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography","volume":"339","author":"Adams","year":"1998","journal-title":"N Engl J Med."},{"key":"B23","first-page":"445","article-title":"Sickle cell disease: primary stroke prevention","volume":"9","author":"Gebreyohanns","year":"2004","journal-title":"CNS Spectr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"CD003146","DOI":"10.1002\/14651858.CD003146.pub2","article-title":"Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease","volume":"1","author":"Wang","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"272940","DOI":"10.1155\/2010\/272940","article-title":"Iron overload in sickle cell disease","volume":"2010","author":"Raghupathy","year":"2010","journal-title":"Adv Hematol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1537-2995.2010.03024.x","article-title":"NHLBI Alloimmunization Working Group. Current problems and future directions of transfusion-induced alloimmunization: summary of an NHLBI working group","volume":"51","author":"Zimring","year":"2011","journal-title":"Transfusion."},{"key":"B27","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3324\/haematol.2019.224709","article-title":"Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal","volume":"105","author":"Thein","year":"2020","journal-title":"Haematologica."},{"key":"B28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1182\/asheducation-2016.1.457","article-title":"Immunoregulatory networks in sickle cell alloimmunization","volume":"2016","author":"Yazdanbakhsh","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"B29","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1182\/asheducation-2016.1.452","article-title":"Cellular immune responses in red blood cell alloimmunization","volume":"2016","author":"Zimring","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"B30","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/bjh.13339","article-title":"Delayed haemolytic transfusion reaction in adults with sickle cell disease: a 5-year experience","volume":"169","author":"Vidler","year":"2015","journal-title":"Br J Haematol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"937846","DOI":"10.1155\/2013\/937846","article-title":"The Association of CD81 polymorphisms with alloimmunization in sickle cell disease","volume":"2013","author":"Tatari-Calderone","year":"2013","journal-title":"Clin Dev Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1080\/03630260701699912","article-title":"Magnetic resonance imaging assessment of excess iron in thalassaemia, sickle cell disease and other iron overload diseases","volume":"32","author":"Wood","year":"2008","journal-title":"Hemoglobin."},{"key":"B33","doi-asserted-by":"publisher","first-page":"270546","DOI":"10.3324\/haematol.2020.270546","article-title":"Red cell transfusion and alloimmunization in sickle cell disease","volume":"6","author":"Linder","year":"2021","journal-title":"Haematologica"},{"key":"B34","doi-asserted-by":"publisher","first-page":"768","DOI":"10.3390\/diagnostics10100768","article-title":"Real-world experience measurement of liver iron concentration by R2 vs. R2 Star MRI in hemoglobinopathies","volume":"10","author":"Abou Zahr","year":"2020","journal-title":"Diagnostics."},{"key":"B35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/ajh.20402","article-title":"Comparison of organ dysfunction in transfused patients with SCD or \u03b2 thalassemia","volume":"80","author":"Vichinsky","year":"2005","journal-title":"Am J Hematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1365-2141.2006.06277.x","article-title":"Oxidative stress and inflammation in iron-overloaded patients with \u03b2-thalassaemia or sickle cell disease","volume":"135","author":"Walter","year":"2006","journal-title":"Br J Haematol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1600-0609.2010.01449.x","article-title":"Patterns of liver iron accumulation in patients with sickle cell disease and thalassemia with iron overload","volume":"85","author":"Hankins","year":"2010","journal-title":"Eur J Haematol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/jmri.10332","article-title":"A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload","volume":"18","author":"Westwood","year":"2003","journal-title":"J Magn Reson Imaging."},{"key":"B39","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1182\/blood-2004-01-0177","article-title":"Non-invasive measurement and imaging of liver iron concentrations using proton magnetic resonance","volume":"105","author":"St. Pierre","year":"2005","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1182\/blood.V89.3.739","article-title":"Iron-chelating therapy and the treatment of thalassemia","volume":"89","author":"Olivieri","year":"1997","journal-title":"Blood."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3324\/haematol.2016.147181","article-title":"Altered heme-mediated modulation of dendritic cell function in sickle cell alloimmunization","volume":"101","author":"Godefroy","year":"2016","journal-title":"Haematologica."},{"key":"B42","doi-asserted-by":"publisher","first-page":"55172","DOI":"10.3791\/55172","article-title":"Continuous manual exchange transfusion for patients with sickle cell disease: an efficient method to avoid iron overload","volume":"121","author":"Koehl","year":"2017","journal-title":"J Vis Exp."},{"key":"B43","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/bjh.13280","article-title":"Therapeutic phlebotomy is safe in children with sickle cell anemia and can be effective treatment for transfusional iron overload","volume":"169","author":"Aygun","year":"2015","journal-title":"Br J Haematol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1182\/blood-2009-02-203323","article-title":"Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury","volume":"114","author":"Adamkiewicz","year":"2009","journal-title":"Blood."},{"key":"B45","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1365-2141.2012.09060.x","article-title":"Serum ferritin and total units transfused for assessing iron overload in adults with sickle cell disease","volume":"157","author":"Drasar","year":"2012","journal-title":"Br J Haematol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1002\/pbc.26017","article-title":"Transfusional iron overload in a cohort of children with sickle cell disease: impact of magnetic resonance imaging, transfusion method, and chelation","volume":"63","author":"Stanley","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1111\/j.1537-2995.2008.01775.x","article-title":"Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions","volume":"48","author":"Fung","year":"2008","journal-title":"Transfusion."},{"key":"B48","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1002\/ajh.23650","article-title":"Ferritin trends do not predict changes in total body iron in patients with transfusional iron overload","volume":"89","author":"Puliyel","year":"2014","journal-title":"Am J Hematol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/trf.13961","article-title":"Severe cardiac iron toxicity in two adults with sickle cell disease","volume":"57","author":"Oduor","year":"2017","journal-title":"Transfusion."},{"key":"B50","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/j.amjmed.2005.02.021","article-title":"Heart failure in beta-thalassemia syndromes: a decade of progress","volume":"118","author":"Hahalis","year":"2005","journal-title":"Am J Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.freeradbiomed.2014.03.039","article-title":"Physiology and pathophysiology of iron in hemoglobin-associated diseases","volume":"72","author":"Coates","year":"2014","journal-title":"Free Radic Biol Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/bjh.14575","article-title":"How we manage iron overload in sickle cell patients","volume":"177","author":"Coates","year":"2017","journal-title":"Br J Haematol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.731102\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,25]],"date-time":"2021-10-25T02:12:20Z","timestamp":1635127940000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2021.731102\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,25]]},"references-count":52,"alternative-id":["10.3389\/fmed.2021.731102"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2021.731102","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,25]]},"article-number":"731102"}}